New York, NY (PRWEB) May 24, 2013
The Icahn School of Medicine at Mount Sinai has granted Cellular Dynamics International (CDI) exclusive license rights to commercially develop cardiomyocyte progenitors for in vivo cell therapy and regenerative medicine applications. These cells are capable of further differentiation into the multiple cell types of the heart, including cardiomyocytes, endothelial cells, and vascular smooth muscle cells, and thus could be used as a potential therapeutic for damaged heart tissue.
The original agreement announced in May 2009 was of an exclusive CDI license to a key patent portfolio surrounding the differentiation of stem cells into human cardiovascular progenitor cells as tools for research use only. Under the new agreement, CDI now can make use of, distribute, sublicense and sell cellular products that employ the licensed technology for therapeutic use.
The licensed technology is based on research first conducted by Gordon Keller, PhD, a former Professor of Gene and Cell Medicine at the Icahn School of Medicine at Mount Sinai who is now Director and Senior Scientist, McEwen Centre for Regenerative Medicine, University Health Network Division of Stem Cell and Developmental Biology, Ontario Cancer Institute, and, two former Postdoctoral Fellows at Mount Sinai, Steve Kattman, PhD, now Group Leader at CDI, and Lei Yang, PhD, now Assistant Professor, Department of Developmental Biology, University of Pittsburgh.
The new agreement was negotiated through Blue Mountain Technologies, a program of Mount Sinai Innovation Partners (Mount Sinai IP), as part of the Icahn School of Medicine at Mount Sinai, that encourages the commercialization of novel research reagents, diagnostics, and therapeutics based on research conducted at the Icahn School of Medicine at Mount Sinai.
“It has been a pleasure working with CDI through this process,” said Felipe Araujo, PhD, Director of Blue
Copyright©2012 Vocus, Inc.
All rights reserved